Anti-IL-23p19 agents have emerged as a promising therapeutic class, demonstrating favorable safety and immunogenicity profiles that position them as potential first-line treatments for moderate-to-severe IBD, with added clinical value for patients presenting concurrent IL-23-driven inflammatory comorbidities such as psoriasis or psoriatic arthritis. This evidence concerns the gene IL37 and psoriasis.